AZTR צמיחת רווח למניה השנה Azitra Corporation

Azitra, Inc. aims for the global implementation of bioengineered skin treatments through B2B partnerships, paving the way for superprofits driven by the low cost of its scalable platform. A comparison of EPS with the same period last year demonstrates profit dynamics, with the latest figure standing at 91.50. The company is currently in the early stages of trials; therefore, its financial condition is entirely dependent on venture capital investments.

The eps_yy_co metric measures the year-over-year growth rate of earnings per share, reflecting the efficiency of capital generation. For Azitra, Inc. (AZTR), this metric confirms the ability to optimize costs associated with complex bioreagent logistics amid rising inflation. By analyzing the annual dynamics of earnings per share, an investor determines the business's actual resilience to rising resource costs and the risks of capital stagnation.